Target intelligence / Profile preview

Gastrointestinal luminal noxious agents

Molecular classification
Other
01

Overview

Gastrointestinal luminal noxious agents encompass a diverse group of harmful substances including bacterial toxins (e.g., endotoxins), pathogenic viruses, bacteria, and reactive oxygen species (free radicals) present within the gut (StatPearls, 2023). These entities are not traditional molecular targets like receptors or enzymes but are instead pathological factors that disrupt the intestinal epithelial barrier and provoke inflammatory cascades (PubMed, PMID: 10648265). Their presence is associated with a wide range of conditions, from acute secretory diarrhea and food poisoning to chronic inflammatory bowel diseases (NIH, 2022). Therapeutic strategies targeting these agents often rely on non-specific physical mechanisms rather than high-affinity molecular binding. For instance, adsorbents like activated charcoal and diosmectite are used to sequester toxins and pathogens, preventing their systemic absorption or local irritation (PubChem, 2024). Similarly, antioxidants and mucosal protectants may be employed to neutralize free radicals and shield the intestinal wall, thereby mitigating oxidative damage and supporting the restoration of normal gastrointestinal homeostasis (PubMed, PMID: 12716233).

Other names
GI luminal toxinsEnteric pathogensIntestinal free radicalsGastrointestinal stressorsLuminal antigens
02

Mechanism of action

Non-specific physical adsorption of toxins and pathogens, mucosal coating and protection, and scavenging of reactive oxygen species to prevent epithelial damage.

03

Biological functions

PathogenesisOxidative stressInfectionToxicity
04

Disease associations

DiarrheaGastroenteritisFood poisoningInflammatory bowel diseaseDysbiosisIntestinal hyperpermeability
05

Safety considerations

Non-specific adsorption of co-administered therapeutic medicationsConstipationElectrolyte imbalancePotential for intestinal obstruction with high doses of adsorbents
06

Interacting drugs

Activated charcoal

6 more in the full profile.

07

Biomarkers

Fecal calprotectinStool toxin assays (e.g., Clostridioides difficile Toxin A/B)Stool cultureFecal occult bloodC-reactive protein

Beyond the preview

Go deeper on Gastrointestinal luminal noxious agents.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal luminal noxious agents.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call